ARNA Arena Pharmaceuticals, Inc.

-0.05  -4%
Previous Close 1.36
Open 1.36
Price To book 16.19
Market Cap 415.84M
Shares 317,435,000
Volume 1,225,879
Short Ratio 4.76
Av. Daily Volume 2,478,570

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2017.
Primary biliary cholangitis (PBC)
Phase 2 trial initiated March 2017.
Pyoderma gangrenosum (PG)
Phase 2 trial initiated March 2017.
Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD)
Approved June 27, 2012.
Phase 2 enrolling as of May 2017.
Pain associated with Crohn's disease
Phase 2 initiated March 2014. Data released Nov 2014
Smoking cessation
Phase 2 data due by the end of 2017.
Ulcerative colitis
Phase 2 data due July 2017.
Pulmonary Arterial Hypertension

Latest News

  1. Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : May 26, 2017
  2. 5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio
  3. 2 Marijuana Stocks That Rocketed Higher by a Double-Digit Percentage Last Week
  4. Can This Struggling Biotech Become the Next Great Marijuana Stock?
  5. Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and GlycoMimetics
  6. Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Today
  7. Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City
  8. Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference
  9. Edited Transcript of ARNA earnings conference call or presentation 9-May-17 8:30pm GMT
  10. Arena Pharmaceuticals (ARNA) Posts Q1 Loss, Revenues Down
  11. Arena Pharmaceuticals reports 1Q loss
  12. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results
  13. Investor Network: Arena Pharmaceuticals, Inc. to Host Earnings Call
  14. Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?
  15. Arena Pharmaceuticals to Release First Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, May 9, 2017
  16. Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
  17. Arena Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARNA) : April 19, 2017
  18. Arena Pharma (ARNA) Down After Underwritten Public Offering
  19. Biotech Industry Outperforming Major Indexes in 2017: Today's Research Reports on Arena Pharmaceuticals and Cytokinetics
  20. Why Is Arena Pharmaceuticals (ARNA) Down 11.3% Since the Last Earnings Report?